In fact, by analyzing the association between EP300 mutations and drug sensitivity of cancer cell lines, we found that EP300-mutated cancers were more responsive to several cell cycle inhibitors, including AZD7762, Wee1 inhibitor, RO-3306, palbociclib, BI-2536, MK-1775, dinaciclib, ribociclib, and MK-8776 (Figure 5). Here, WEE1 is linked to cancer.